COVID-19

EJoN publishes EAN consensus statement for management of patients with neurological diseases during the COVID‐19 pandemic

Newest addition to Breaking News submitted by Neurooncology Panel: Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas

Newest contribution to Breaking News is by Dementia Panel: Tackling challenges in care of Alzheimer’s disease and other dementias amid the COVID-19 pandemic, now and in the future

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'

For October 2020, we have selected the following Covid-19 paper: Hernández-Fernández F. et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020 Jul 9;awaa239. doi: 10.1093/brain/awaa239. Online ahead of print.

For September 2020, we have selected: The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report.

Alzheimer Europe calls for urgent action to address the impact of COVID-19 on dementia research

In this study recently published in Brain, the authors collected detailed clinical and paraclinical data from patients with suspected COVID-19-related neurological disorders in whom the diagnosis of COVID-19 was confirmed through RNA PCR, or where the diagnosis was probable/possible according to World Health Organisation criteria.

Anosmia, stroke, paralysis, cranial nerve deficits, encephalopathy, delirium, meningitis, and seizures are some of the neurological complications in patients with COVID-19.

In this study, recently published in Brain, the authors present cerebrovascular disease case incidence in hospitalised patients with SARS-CoV-2 infection.

In this paper, the authors retrospectively reviewed all COVID-19–positive patients admitted to the neuroscience intensive care unit for monitoring of malignant cerebral oedema

In this paper recently published in Acta Neuropathologica, the authors report neuropathology of two COVID-19 patients.

In this paper, the authors pooled all consecutive patients hospitalised with laboratory-confirmed COVID-19 and acute ischaemic stroke across 28 sites from 16 countries.

In this paper, the authors report a case of a previously healthy 58-year-old man who acutely developed hyposmia, generalised myoclonus, fluctuating and transient changes in level of consciousness, opsoclonus and an asymmetric hypokinetic-rigid syndrome with ocular abnormalities following severe SARS-CoV-2 infection.

In this review recently published in JAMA, the authors summarise the current evidence regarding the pathophysiology, transmission, diagnosis, and management of COVID-19.